0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Seeking Alpha
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
Allogene Moves Forward With CAR-T Therapy Pipeline Summary Allogene Therapeutics established a partnership with Notch Therapeutics so that both companies can develop iPSC AlloCar therapy products. The pluripotent stem cells from Notch provide an inexhaustible source along with other advantages like developing T-cells and other immune cells from clonal stem cell lines. Allogene has already established its own AlloCAR T therapy for the treatment of hematological malignancies and solid tumors. Allogene Therapeutics has $601.9 million in cash as of September 30, 2019, which will be enough to fund operations 12 months from the November 5, 2019, 10-Q SEC Filing. Allogene Therapeutics ( ALLO latest partnership involves Notch Therapeutics Partnership Advances Deep Dive Into New Type Of nology Allogene Therapeutics has formed a worldwide collaboration and license agreement with Notch Therapeutics. This agreement was made so that both companies could research and develop iPSC AlloCAR therapy pr [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Seeking Alpha
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
Allogene Moves Forward With CAR-T Therapy Pipeline Summary Allogene Therapeutics established a partnership with Notch Therapeutics so that both companies can develop iPSC AlloCar therapy products. The pluripotent stem cells from Notch provide an inexhaustible source along with other advantages like developing T-cells and other immune cells from clonal stem cell lines. Allogene has already established its own AlloCAR T therapy for the treatment of hematological malignancies and solid tumors. Allogene Therapeutics has $601.9 million in cash as of September 30, 2019, which will be enough to fund operations 12 months from the November 5, 2019, 10-Q SEC Filing. Allogene Therapeutics ( ALLO latest partnership involves Notch Therapeutics Partnership Advances Deep Dive Into New Type Of nology Allogene Therapeutics has formed a worldwide collaboration and license agreement with Notch Therapeutics. This agreement was made so that both companies could research and develop iPSC AlloCAR therapy pr [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS